Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
U-Neuron BiomedicalROCO:6973 +4.74%36 Cash Ratio is 9.76 as of Jun. 2026, which is 37% below its 10-year median of 15.41. GuruFocus rates ROCO:6973 with a GF Score™ of 36/100 and a GF Value™ of NT$70.50 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,381 Biotechnology companies, U-Neuron Biomedical ranks better than 79.36% on this metric.
U-Neuron Biomedical has a Cash Ratio of 9.76. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for U-Neuron Biomedical's Cash Ratio or its related term are showing as below:
ROCO:6973'
s Cash Ratio Range Over the Past 10 Years
Min: 7.16 Med: 15.41 Max: 30.9
Current: 9.76
During the past 6 years, U-Neuron Biomedical's highest Cash Ratio was 30.90. The lowest was 7.16. And the median was 15.41.
ROCO:6973's Cash Ratio is ranked better than 79.36% of 1381
companies
in the Biotechnology industry
Industry Median: 2.96
vs ROCO:6973: 9.76
U-Neuron Biomedical (ROCO:6973) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
U-Neuron Biomedical Cash Ratio Related Terms
U-Neuron Biomedical Cash Ratio Historical Data
* Premium members only.
The historical data trend for U-Neuron Biomedical's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6973 vs VRTX, REGN, MRNA: Cash Ratio Comparison
For the Biotechnology subindustry, U-Neuron Biomedical's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
U-Neuron Biomedical Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, U-Neuron Biomedical's Cash Ratio distribution charts can be found below:
* The bar in red indicates where U-Neuron Biomedical's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
U-Neuron Biomedical (ROCO:6973) has a Cash Ratio of 9.76 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on U-Neuron Biomedical and its competitors. This is 37% below median its historical median of 15.41. Over the past decade, U-Neuron Biomedical's Cash Ratio has ranged from 7.16 to 30.90. According to the industry distribution chart, U-Neuron Biomedical ranks #285 out of 1381 companies in the Biotechnology industry, placing it in the top 20.6%.
Is U-Neuron Biomedical's Cash Ratio too high?
U-Neuron Biomedical's current Cash Ratio of 9.76 is 37% below median its 10-year median of 15.41. Over the past 10 years, this metric has ranged from a low of 7.16 to a high of 30.90. The Biotechnology industry median Cash Ratio is 2.96. U-Neuron Biomedical's value of 9.76 is 229.7% above this industry median. Based on the distribution chart, U-Neuron Biomedical ranks #285 out of 1381 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, U-Neuron Biomedical has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does U-Neuron Biomedical's Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, U-Neuron Biomedical ranks #285 out of 1381 companies for Cash Ratio. This places U-Neuron Biomedical in the top 21% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.96. U-Neuron Biomedical's value of 9.76 is 229.7% above this benchmark. Historically, U-Neuron Biomedical's own Cash Ratio has ranged from 7.16 to 30.90 over the past decade. While the company's 10-year median is 15.41 vs. the industry median of 2.96, U-Neuron Biomedical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.96, based on 1,381 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. U-Neuron Biomedical's current Cash Ratio of 9.76 is 229.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on U-Neuron Biomedical and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. U-Neuron Biomedical's current Cash Ratio is 9.76, which is 37% below median its own 10-year median of 15.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is U-Neuron Biomedical stock overvalued right now?
Based on GuruFocus' analysis, U-Neuron Biomedical (ROCO:6973) is currently considered Possible Value Trap. The stock's GF Value™ is NT$70.50, compared to a current price of NT$47.50 — trading 32.6% below its estimated fair value. The current Cash Ratio is 9.76, which is 37% below median its 10-year median of 15.41 and 229.7% above the Biotechnology industry median of 2.96. U-Neuron Biomedical's overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For U-Neuron Biomedical (ROCO:6973), the current Cash Ratio is 9.76 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is U-Neuron Biomedical (ROCO:6973) Overvalued in 2026?
Based on GuruFocus' analysis, U-Neuron Biomedical stock appears to be undervalued.
The current stock price of NT$47.50 is trading 32.6% below its estimated GF Value™ of NT$70.50.
GuruFocus considers U-Neuron Biomedical to be Possible Value Trap.
Key valuation signals for ROCO:6973:
Cash Ratio: 9.76 (37% below median its 10-year median of 15.41)
GF Value™: NT$70.50 vs. price of NT$47.50 (32.6% below fair value)
Industry Position: 229.7% above the Biotechnology median (#285 of 1381)
No single metric tells the full story. See the ROCO:6973 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
U-Neuron Biomedical Inc is engaged in research and development of stem cell storage & separation technology, and treatment application technology. It has patent on the Technology of Culture and Isolation of Amniotic Fluid Stem Cell.
36GF Score
Get the complete analysis for ROCO:6973
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6973 has been successfully added to your 
